Australian doctors say they have developed new scans that can that quickly show whether breast cancer cells are responding to therapy.
After a six-year trial, doctors at the Peter MacCallum Cancer Center say the scans can improve treatment and "buy valuable time for breast cancer sufferers by abandoning ineffective treatments in the early stages."
The newspaper said the PET (positron emission tomography) scans reveal the information within weeks, instead of months using conventional CT scans.
"Normally we have to wait for months before a CT scan will start to improve," Rod Hicks, head of molecular imaging at the center, told the newspaper. "With this treatment we know that if it hasn't responded quickly, it's not going to respond and we can move on and try something else."
Researchers said conventional CT scans show only the structure of cancer cells, but PET scans reveal the physiology of tumors and allows doctors to localize treatment to the exact site of the cancer, the newspaper said.
Copyright 2006 by United Press International
Related stories:
Potential remedy for the 'mental fog' in cancer patients
Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University (WVU), researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce. The WVU researchers' study has just been published in the September issue of the Springer journal
Metabolic Brain Disease.
PET scans lead to treatment changes in majority of colorectal cancer patients
In the largest multi-institutional study to date examining the impact of positron emission tomography (PET) in changing disease management of individuals with suspected recurrent colorectal cancer, researchers found that treatment plans were changed for more than half of patients, according to an article in the September issue of
The Journal of Nuclear Medicine.
Gene that causes childhood cancer neuroblastoma is found
Scientists have discovered gene mutations that are the main cause of the inherited version of the childhood cancer neuroblastoma. In addition, the researchers found that the same mutations play a significant role in high-risk forms of non-inherited neuroblastoma, the more common form of the disease.
Dual-Mode Nanoparticles Image Tumors Using MRI and PET
Medical imaging represents one of the most used and useful procedures in the oncologist’s diagnostic toolkit, even though each of the most useful techniques—magnetic resonance imaging (MRI), computerized tomography x-ray imaging (CT), and positron emission tomography (PET) scanning—has its own set of limitations.
Teamwork cuts out unnecessary biopsies, researchers find
Unnecessary biopsies could be a thing of the past for patients undergoing treatment for head and neck cancer. New Saint Louis University research found that when nuclear medicine clinicians and treating physicians work together to interpret PET-CT scan results, the accuracy dramatically improves, sparring patients unnecessary pain and suffering.
Has cancer spread? Research identifies best way to find answers so treatment can begin
For patients with head and neck cancer, accurately determining how advanced the cancer is and detecting secondary cancers usually means undergoing numerous tests – until now. New Saint Louis University research has found that the PET-CT scanner can be used as a stand-alone tool to detect secondary cancers, which occur in 5 to 10 percent of head and neck cancer patients.
Brain cancer study: Magnitude of post-vaccine immune response linked to clinical outcomes
Researchers conducting a clinical trial of a dendritic cell vaccine designed to fight malignant brain tumors called glioblastoma multiforme (GBM) have found a correlation between the "intensity" of a patient's immune response and clinical outcome, according to an article in the July 15 issue of the journal
Cancer Research.
Blood vessel inhibitor shows promise against metastatic thyroid cancer
Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M. D. Anderson Cancer Center reports in the July 3rd edition of
The New England Journal of Medicine.